J. Solassol

J. Pignon, B. Chetaille, J. Solassol, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome

J. Solassol, I. Solassol, J. Vendrell, 2021, Translational lung cancer research.

Specific increase of human kallikrein 4 mRNA and protein levels in breast cancer stromal cells.

J. Solassol, A. Mangé, T. Maudelonde, 2008, Biochemical and biophysical research communications.

Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches

P. Brousset, J. Mazières, J. Solassol, 2017, Scientific Reports.

Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer

I. Bièche, J. Solassol, H. Blons, 2013 .

Rare epidermal growth factor receptor (EGFR) mutations in 10,117 patients with non-small cell lung cancer (NSCLC) evaluated by the French ERMETIC IFCT network: Clinical, molecular, and survival data.

J. Solassol, H. Blons, F. Escande, 2012 .

Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer

P. Colombo, P. Rouanet, J. Solassol, 2020, Cancers.

Challenging BRAF/EGFR co-inhibition in NSCLC using sequential liquid biopsies.

J. Solassol, J. Vendrell, X. Quantin, 2019, Lung cancer.

Investigation of pre-XDR Beijing Mycobacterium tuberculosis transmission to a healthcare worker in France, 2016.

J. Solassol, S. Godreuil, W. Sougakoff, 2017, The Journal of hospital infection.

A novel copper-hydrogen peroxide formulation for prion decontamination.

J. Solassol, S. Lehmann, M. Pastore, 2006, The Journal of infectious diseases.

Establishment and characterization of a cell line from human circulating colon cancer cells.

Udo Schumacher, Jérôme Solassol, Klaus Pantel, 2015, Cancer research.

[Interest of blood markers in predicting radiation-induced toxicity].

J. Solassol, M. Ozsahin, D. Azria, 2011, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

High Nasal Carriage Rate of Staphylococcus aureus Containing Panton-Valentine leukocidin- and EDIN-Encoding Genes in Community and Hospital Settings in Burkina Faso

J. Solassol, P. Van de Perre, C. Dunyach-Rémy, 2016, Front. Microbiol..

Detection of prion after decontamination procedures: comparative study of standard Western blot, filter retention and scrapie-cell assay.

J. Solassol, M. Arlotto, S. Lehmann, 2004, The Journal of hospital infection.

Elevated concentrations of milk β2-microglobulin are associated with increased risk of breastfeeding transmission of HIV-1 (Vertical Transmission Study).

J. Solassol, A. Mangé, P. Van de Perre, 2013, Journal of proteome research.

Proteomic analysis of differently archived breast cancer tissues.

J. Solassol, A. Mangé, A. Bougnoux, 2012, Cancer genomics & proteomics.

Evaluating ZNF217 mRNA Expression Levels as a Predictor of Response to Endocrine Therapy in ER+ Breast Cancer

B. Győrffy, P. Rouanet, J. Solassol, 2019, Front. Pharmacol..

FKBP4 connects mTORC2 and PI3K to activate the PDK1/Akt-dependent cell proliferation signaling in breast cancer

B. Raught, J. Solassol, A. Mangé, 2019, Theranostics.

ifCNV: A novel isolation-forest-based package to detect copy-number variations from various targeted NGS datasets

Laurent A. F. Frantz, J. Solassol, J. Vendrell, 2022, Molecular therapy. Nucleic acids.

Comparison of five cell-free DNA isolation methods to detect the EGFR T790M mutation in plasma samples of patients with lung cancer

E. Diamandis, J. Solassol, A. Mangé, 2018, Clinical chemistry and laboratory medicine.

High Prevalence of SXT/R391-Related Integrative and Conjugative Elements Carrying blaCMY-2 in Proteus mirabilis Isolates from Gulls in the South of France

J. Solassol, J. Lavigne, S. Godreuil, 2015, Antimicrobial Agents and Chemotherapy.

A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms.

J. Pignon, J. Mosser, I. Bièche, 2014, The Journal of molecular diagnostics : JMD.

High-throughput detection of clinically targetable alterations using next-generation sequencing

P. Brousset, J. Solassol, V. Costes, 2017, Oncotarget.

Circulating Cell Free Tumor DNA Detection as a Routine Tool for Lung Cancer Patient Management

J. Solassol, J. Vendrell, S. Godreuil, 2017, International journal of molecular sciences.

Comparative Methods to Improve the Detection of BRAF V600 Mutations in Highly Pigmented Melanoma Specimens

J. Solassol, V. Costes, T. Maudelonde, 2016, PloS one.

Alu element insertion in the MLH1 exon 6 coding sequence as a mutation predisposing to Lynch syndrome

J. Solassol, P. Pujol, J. Chiésa, 2019, Human mutation.

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations

J. Solassol, M. Fabbro, Stanislas Quesada, 2022, Cancers.

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives

J. Solassol, M. Fabbro, Stanislas Quesada, 2022, Cancers.

PTPN13 induces cell junction stabilization and inhibits mammary tumor invasiveness

Romain M. Larive, J. Solassol, A. Naldi, 2020, Theranostics.

Comprehensive proteomic analysis of the human milk proteome: contribution of protein fractionation.

J. Solassol, A. Mangé, E. Tuaillon, 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Simultaneous absolute quantification of target and control templates by real-time fluorescence reverse transcription-PCR using 4-(4'-dimethylaminophenylazo)benzoic acid as a dark quencher dye.

J. Solassol, K. Kreuzer, A. Bohn, 2001, Clinical chemistry.

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.

J-L Pretet, I. Bièche, J. Solassol, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches

P. Brousset, J. Mazières, J. Solassol, 2017, Scientific Reports.

Multi-Center Evaluation of the Fully Automated PCR-Based Idylla™ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal Cancer

M. Fassan, J. Solassol, B. Bellosillo, 2016, PloS one.

Benchmarking of Amplicon-Based Next-Generation Sequencing Panels Combined with Bioinformatics Solutions for Germline BRCA1 and BRCA2 Alteration Detection.

J. Solassol, J. Vendrell, M. Larrieux, 2018, The Journal of molecular diagnostics : JMD.

Clinical Relevance of Autoantibody Detection in Lung Cancer

J. Solassol, A. Mangé, T. Maudelonde, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Quantitative Proteomic Approach of the Different Stages of Colorectal Cancer Establishes OLFM4 as a New Nonmetastatic Tumor Marker*

M. Campone, J. Solassol, E. Gamelin, 2011, Molecular & Cellular Proteomics.

ifCNV: a novel isolation-forest-based package to detect copy number variations from various NGS datasets

Laurent A. F. Frantz, J. Solassol, J. Vendrell, 2022, bioRxiv.

TERT Promoter Mutation as an Independent Prognostic Marker for Poor Prognosis MAPK Inhibitors-Treated Melanoma

J. Solassol, É. Coyaud, J. Vendrell, 2020, Cancers.

Combination of tissue and liquid biopsy molecular profiling to detect transformation to small cell lung carcinoma during osimertinib treatment

J. Solassol, J. Vendrell, I. Serre, 2020, Therapeutic advances in medical oncology.

Ultra-sensitive EGFRT790M Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring EGFRdel19 Mutations and Treated with First-generation TKIs

P. Brousset, J. Mazières, J. Solassol, 2019, Clinical Cancer Research.

Proximal Protein Interaction Landscape of RAS Paralogs

B. Raught, J. Solassol, A. Mangé, 2020, Cancers.

Comparative evaluation of the new FDA approved THxID™-BRAF test with high resolution melting and sanger sequencing

J. Solassol, A. Mangé, V. Costes, 2014, BMC Cancer.

First Description of IncX3 Plasmids Carrying blaOXA-181 in Escherichia coli Clinical Isolates in Burkina Faso

J. Solassol, J. Vendrell, S. Godreuil, 2016, Antimicrobial Agents and Chemotherapy.

Psychosocial and clinical factors of probands impacting intrafamilial disclosure and uptake of genetic testing among families with BRCA1/2 or MMR gene mutations

M. Picot, J. Solassol, P. Pujol, 2019, Psycho-oncology.

Reconstruction and signal propagation analysis of the Syk signaling network in breast cancer cells

Aurélien Naldi, Ovidiu Radulescu, Urszula Czerwinska, 2017, PLoS Comput. Biol..

FKBP family proteins as promising new biomarkers for cancer.

J. Solassol, A. Mangé, T. Maudelonde, 2011, Current opinion in pharmacology.

High prevalence and characterization of extended-spectrum ß-lactamase producing Enterobacteriaceae in Chadian hospitals

J. Solassol, J. Benavides, S. Godreuil, 2019, BMC Infectious Diseases.

Humoral response to cancer as a tool for biomarker discovery.

J. Solassol, A. Mangé, C. Desmetz, 2009, Journal of proteomics.

Identifying autoantibody signatures in cancer: a promising challenge

J. Solassol, A. Mangé, T. Maudelonde, 2009, Expert review of proteomics.

Improvement of protein immobilization for the elaboration of tumor-associated antigen microarrays: application to the sensitive and specific detection of tumor markers from breast cancer sera.

J. Solassol, A. Mangé, É. Souteyrand, 2013, Biosensors & bioelectronics.

Identification of a New Panel of Serum Autoantibodies Associated with the Presence of In situ Carcinoma of the Breast in Younger Women

P. Rouanet, C. Bascoul-Mollevi, J. Solassol, 2009, Clinical Cancer Research.

Serum Autoantibody Signature of Ductal Carcinoma In Situ Progression to Invasive Breast Cancer

P. Rouanet, C. Bascoul-Mollevi, J. Solassol, 2012, Clinical Cancer Research.

Thiopurine Drugs in the Treatment of Ulcerative Colitis: Identification of a Novel Deleterious Mutation in TPMT

J. Solassol, Pierre-Olivier Harmand, 2020, Genes.

The contribution of proteomics to the identification of biomarkers for cutaneous malignant melanoma.

J. Solassol, A. Bougnoux, 2013, Clinical biochemistry.

Serum Proteomic Profiling Reveals Potential Biomarkers for Cutaneous Malignant Melanoma

J. Solassol, T. Maudelonde, B. Guillot, 2011, The International journal of biological markers.

An integrated cell line-based discovery strategy identified follistatin and kallikrein 6 as serum biomarker candidates of breast carcinoma.

E. Diamandis, J. Solassol, A. Mangé, 2016, Journal of proteomics.

Exploring the Significance of the Exon 4-Skipping Isoform of the ZNF217 Oncogene in Breast Cancer

B. Győrffy, J. Lachuer, J. Solassol, 2021, Frontiers in Oncology.

Detection of BRAF V600 Mutations in Melanoma: Evaluation of Concordance between the Cobas® 4800 BRAF V600 Mutation Test and the Methods Used in French National Cancer Institute (INCa) Platforms in a Real-Life Setting

J. Solassol, J. Scoazec, J. Merlin, 2015, PloS one.

Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early‐stage breast cancers

P. Rouanet, C. Bascoul-Mollevi, J. Solassol, 2013, International journal of cancer.

Prion propagation in cultured cells.

J. Solassol, S. Lehmann, C. Crozet, 2003, British medical bulletin.

Comparative evaluation of the new FDA approved THxID™-BRAF test with high resolution melting and sanger sequencing

J. Solassol, A. Mangé, V. Costes, 2014, BMC Cancer.

Anti-heat shock protein autoantibody profiling in breast cancer using customized protein microarray

J. Solassol, A. Mangé, É. Souteyrand, 2016, Analytical and Bioanalytical Chemistry.

Cell Culture Models of TSEs

J. Solassol, V. Perrier, S. Lehmann, 2004 .

[Cell culture models of transmissible spongiform encephalopathies].

J. Solassol, A. Mangé, H. Laude, 2001, Comptes rendus biologies.

Dzip1 and Fam92 form a ciliary transition zone complex with cell type specific roles in Drosophila

B. Durand, J. Solassol, A. Mangé, 2019, eLife.

HDL Proteome in Hemodialysis Patients: A Quantitative Nanoflow Liquid Chromatography-Tandem Mass Spectrometry Approach

J. Solassol, A. Mangé, T. Maudelonde, 2012, PloS one.

Detection of trisomy 21 by quantitative fluorescent–polymerase chain reaction in uncultured amniocytes

B. Dastugue, J. Solassol, Haíssam Rahil, 2003, Prenatal diagnosis.

Liquid chromatography-tandem and MALDI imaging mass spectrometry analyses of RCL2/CS100-fixed, paraffin-embedded tissues: proteomics evaluation of an alternate fixative for biomarker discovery.

P. Chaurand, R. Caprioli, J. Solassol, 2009, Journal of proteome research.

Proteomic profile determination of autosomal aneuploidies by mass spectrometry on amniotic fluids

J. Solassol, A. Mangé, T. Maudelonde, 2008, Proteome Science.

Serum Proteomic Profiling of Lung Cancer in High-Risk Groups and Determination of Clinical Outcomes

J. Daurès, J. Solassol, A. Mangé, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Use of Autoantibodies to Detect the Onset of Breast Cancer

J. Solassol, A. Mangé, J. Lacombe, 2014, Journal of immunology research.

A Multiparametric Serum Marker Panel as a Complementary Test to Mammography for the Diagnosis of Node-Negative Early-Stage Breast Cancer and DCIS in Young Women

J. Solassol, A. Mangé, I. Prassas, 2014, Cancer Epidemiology, Biomarkers & Prevention.

Proteomic analysis of RCL2 paraffin-embedded tissues

J. Solassol, A. Mangé, T. Maudelonde, 2008, Journal of cellular and molecular medicine.

Highly sensitive detection of melanoma based on serum proteomic profiling

Jérôme Solassol, Bernard Guillot, Alain Mangé, 2009, Journal of Cancer Research and Clinical Oncology.

[Proteomic profiling: the potential of Seldi-Tof for the identification of new cancer biomarkers].

P. Marin, J. Solassol, A. Mangé, 2005, Bulletin du cancer.

Cutaneous Epithelial Tumors Induced by Vemurafenib Involve the MAPK and Pi3KCA Pathways but Not HPV nor HPyV Viral Infection

J. Solassol, V. Costes, N. Boulle, 2014, PloS one.